LaserCap Company participated in an independent hair regrowth clinical trial, conducted from 2022 through 2025, in partnership with the University of Arizona School of Medicine. The study evaluated treatment response to The Original LaserCap, in men and women with androgenetic alopecia.
Key Takeaways
- Double-blinded, placebo-controlled design: The study enrolled 50 men and women with androgenetic alopecia and compared the results of treatment with LaserCap HD+, LaserCap SD, and a sham device over 26 weeks.
- Results indicated efficacy and dose response: Both active LaserCap devices significantly increased total hair count compared with sham, with the higher-fluence LaserCap HD+ producing the largest improvement.
- Independent Study: LaserCap Company supplied study devices, but did not provide other financial support and was not involved in the study design or execution.
- Accepted for presentation at AAD: The study results were accepted for presentation at the 2026 American Academy of Dermatology Annual Meeting, as part of their continuing medical education program. Publication is pending in the Journal of the American Academy of Dermatology.
Study Design: An Independent Hair Regrowth Clinical Trial
The Original LaserCap hair regrowth clinical trial was conducted between 2022 and 2025, in partnership with the University of Arizona School of Medicine Dermatology Department. Researchers enrolled 50 men and women with androgenetic alopecia, also called Male Pattern Hair Loss or Female Pattern Hair Loss, and assigned participants to LaserCap HD+, LaserCap SD, or a sham device in a double-blind, placebo-controlled study.
After 26 weeks, researchers assessed outcomes with phototrichogram analysis and global photography. This hair regrowth clinical trial had two goals: verify the effectiveness of LaserCap’s high-strength treatment protocol for androgenetic alopecia and examine whether a higher-fluence treatment produced a greater regrowth response.
LaserCap Company supplied the study devices but did not finance the study or participate in its design or execution. This separated the manufacturer from the research process, avoiding conflicts of interest which could have influenced results. Readers can review the registered study details for more information on study design.
What the Results Showed
After 26 weeks of treatment, phototrichotram analysis demonstrated that both active devices significantly increased total hair count compared with sham. LaserCap HD+ increased total hair count by 18.39 hairs/cm² (p=0.0053), while LaserCap SD increased total hair count by 13.95 hairs/cm² (p=0.0150).
Although both study devices were shown to be effective, the higher-fluence LaserCap HD+ device produced the most robust improvement in total hair count, thereby demonstrating a dose-response effect. This validated the study’s hypothesis that higher fluence (higher dose) red light therapy will result in increased hair growth. It should be noted that this study was unique among red light therapy hair regrowth clinical trials, in that it specifically tested dose response to treatment.
Presented at the 2026 AAD Annual Meeting
The study results were accepted for presentation at the 2026 American Academy of Dermatology Annual Meeting as part of its CME-accredited scientific program. The abstract from the conference is now published. Publication in the Journal of the American Academy of Dermatology (JAAD) is pending.
How LaserCap Clinical Evidence Compares With Other Hair Growth Devices
The study brief compares devices on three criteria: a clinical study using a commercially available model or equivalent, peer-reviewed publication, and independent funding.
| Device | Clinical study1 | Peer-reviewed publication |
Independent2 |
|---|---|---|---|
| The Original LaserCap | Yes | Pending | Yes |
| HairMax LaserComb | Yes | Yes | No |
| Theradome LH80 | Yes | No | No |
| Revian Red | Yes | No | No |
| Capillus devices | No | No | No |
| iRestore devices | No | No | No |
| Kiierr/Illumiflow devices | No | No | No |
1 Clinical study conducted with a commercially available device model or equivalent.
2 Funding for study did not come primarily from the device company.
Evidence-Based Red Light Therapy for Hair Regrowth
If you are suffering from hair loss, red light therapy is the best treatment option available today. There are a number of hair regrowth red light therapy devices you can choose from. Make sure to pick a device with efficacy supported by scientific evidence and a high-quality clinical trial, like The Original LaserCap. Get started with LaserCap today, and start your journey toward thicker, healthier hair.
